Seventy percent of the 20 best-selling drugs in Taiwan are for treating blood pressure, strokes and other chronic diseases.
Several years ago, Pfizer added California-based Alacer to its consumer health business. But now it has decided it doesn't need a plant in California that came with that deal and will close it in May, laying off the 70 workers there.
Akili Interactive Labs has partnered with the nonprofit Autism Speaks to conduct a clinical trial of its cognitive assessment and personalized treatment video game.
Pfizer has updated the risk factors section of its U.S. Securities and Exchange Commission (SEC) filings to reflect the new normal in cybersecurity. The Big Pharma lays out the situation plainly: "As a global pharmaceutical company, our systems are subject to frequent attacks."
Pfizer and Novartis have snagged a nod from the CDC's Advisory Committee on Immunization Practices for their recently approved meningitis B vaccines. There's just one problem: It doesn't cover nearly as large a population as the pharma giants would like.
Here is part two of comments from C-suite execs on emerging markets and Asia in the latest quarterly conference calls.
Pfizer and Novartis officially have a nod from the CDC's Advisory Committee on Immunization Practices (ACIP) for their recently approved meningitis B vaccines. Problem is, it doesn't cover nearly as large a population as the pharma giants would like.
Pfizer is once again trimming its R&D staff. Responding to a query from FierceBiotech regarding word of cutbacks at research facilities in Cambridge, MA, and Collegeville, PA, Pfizer spokesman Dean Mastrojohn sent back a confirmation, later declining to specify just how many jobs are being cut.
Pfizer may have FDA approval for meningitis B vaccine Trumenba, but it can only take the jab so far without a nod from the CDC's Advisory Committee on Immunization Practices (ACIP). Now, though, it's got some positive new data on the shot just in time to help it make its case for one.
An early FDA approval is a bonus for any drug. But for Pfizer's new breast cancer drug Ibrance (palbociclib), the earlier-than-expected green light has given it a billion-dollar-plus boost--on paper, anyway.